# Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease

> **NCT04819841** · PHASE1,PHASE2 · RECRUITING · sponsor: **Kamau Therapeutics** · enrollment: 15 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **GENETIC:** nula-cel Drug Product

## Key facts

- **NCT ID:** NCT04819841
- **Lead sponsor:** Kamau Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04819841

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04819841, "Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04819841. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*